Calcifediol Anhydrous
The anhydrous form of calcifediol, the main circulating vitamin D metabolite used to treat vitamin D deficiency and related bone disorders, particularly in patients with chronic kidney disease. This form is used in specific extended-release formulations designed to raise vitamin D levels gradually. It bypasses the liver hydroxylation step needed to activate dietary vitamin D.
分子量
400.6000 g/mol
LogP
6.20
TPSA
40.50 Ų
リピンスキーの五則
適合
作用機序
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
2D構造
Cite this structure
Embed this structure
SMILES
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12
InChI
InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1
Molecular Formula
C27H44O2
HBD / HBA
2 / 2
回転可能結合数
6
重原子数
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
The anhydrous form of calcifediol, the main circulating vitamin D metabolite used to treat vitamin D deficiency and related bone disorders, particularly in patients with chronic kidney disease. This form is used in specific extended-release formulations designed to raise vitamin D levels gradually. It bypasses the liver hydroxylation step needed to activate dietary vitamin D.
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Yes, Calcifediol Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1040. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5283731. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="calcifediol-anhydrous"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/calcifediol-anhydrous/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/calcifediol-anhydrous/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/calcifediol-anhydrous/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="calcifediol-anhydrous"></drugfyi-drug>